eISSN: 2081-2841
ISSN: 1689-832X
Journal of Contemporary Brachytherapy
Current Issue Archive Supplements Articles in Press Journal Information Aims and Scope Editorial Office Editorial Board Register as Author Register as Reviewer Instructions for Authors Abstracting and indexing Subscription Advertising Information Links
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
5/2022
vol. 14
 
Share:
Send email
Share:
abstract:
Original paper

Superficial high-dose-rate brachytherapy for primary tumors and relapses after surgery in patients with basal cell carcinoma of the head and neck region: results of a retrospective comparative cohort study

Artur J. Chyrek
1
,
Adam Chicheł
1
,
Wojciech M. Burchardt
1, 2
,
Grzegorz Bielęda
2, 3
,
Małgorzata Jankowska
4
,
Jerzy Moczko
5
,
Andrzej Roszak
2, 6

  1. Brachytherapy Department, Greater Poland Cancer Centre, Poznan, Poland
  2. Electroradiology Department, University of Medical Sciences, Poznan, Poland
  3. Medical Physics Department, Greater Poland Cancer Centre, Poznan, Poland
  4. 2nd Radiotherapy Department, Greater Poland Cancer Centre, Poznan, Poland
  5. Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poznan, Poland
  6. Department of Radiotherapy and Oncological Gynecology, Greater Poland Cancer Centre, Poznan, Poland
J Contemp Brachytherapy 2022; 14, 5: 438–445
DOI: https://doi.org/10.5114/jcb.2022.121134
Online publish date: 2022/11/14
View full text Get citation
 
Purpose
The recommended treatments for basal cell carcinoma (BCC) in the head and neck (H&N) region are Mohs surgery, standard surgical excision (SSE), and radiotherapy. According to the literature, local recurrence after surgical treatment in this area is associated with a worse prognosis in case of re-treatment. To our knowledge, there are no reports on high-dose-rate brachytherapy (HDR-BT) for BCC of the H&N region, both in primary lesions and relapses after SSE. This study aimed to fill this gap in the literature.

Material and methods
Inclusion criteria were pathologically confirmed BCC, tumor location in the H&N region, treatment performed with superficial HDR-BT, and a minimum follow-up of 12 months. An analysis was performed on a group of 90 patients, in whom a total of 102 tumors were treated. Subsequently, tumors were divided into two sub-groups, including those treated initially, and treated due to local recurrence after previous SSE. Primary treatment group (PrG) included 59 tumors, whereas 43 tumors were included in recurrent group (ReG).

Results
Statistical analysis did not reveal any significant differences between the groups in terms of age (p = 0.43), treatment duration (p = 0.17), follow-up time (p = 0.96), sex (p = 0.18), local advancement (p = 0.83), and location (p = 0.68). The estimated 5-year relapse-free survival was 96.4% in the PrG and 94.6% in the ReG group, and the difference was not statistically significant (p = 0.72). In the PrG, skin toxicity was as follows: early G1 – 20.3%, G2 – 28.8%, G3 – 42.4%, G4 – 8.5%; late G1 – 33.9%, G2 – 50.8%, G3 – 1.7%, G4 – 11.9%. Whereas, in the ReG, toxicity was as follows: early G1 – 16.3%, G2 – 41.9%, G3 – 37.2%, G4 – 4.6%; late G1 – 30.2%, G2 – 62.8%, G3 – 4.6%. There were no statistically significant differences in the early nor late toxicity between the groups (p = 0.54, p = 0.16).

Conclusions
Superficial HDR-BT is a highly effective treatment for both primary and recurrent BCC of the H&N region, and is associated with acceptable skin toxicity.

keywords:

recurrence, skin cancer, HDR, BCC, head and neck

  
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.